Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.250
-0.060 (-4.58%)
At close: Feb 12, 2026, 4:00 PM EST
1.267
+0.016 (1.32%)
After-hours: Feb 12, 2026, 5:45 PM EST
Biomea Fusion Employees
Biomea Fusion had 42 employees as of September 30, 2025. The number of employees decreased by 65 or -60.75% compared to the same quarter last year.
Employees
42
Change
-65
Growth
-60.75%
Revenue / Employee
n/a
Profits / Employee
-$2,278,833
Market Cap
88.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 42 | -65 | -60.75% |
| Jun 30, 2025 | 63 | -49 | -43.75% |
| Mar 31, 2025 | 79 | -31 | -28.18% |
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Sep 30, 2024 | 107 | 4 | 3.88% |
| Jun 30, 2024 | 112 | 18 | 19.15% |
| Mar 31, 2024 | 110 | 24 | 27.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Sep 30, 2023 | 103 | 28 | 37.33% |
| Jun 30, 2023 | 94 | 22 | 30.56% |
| Mar 31, 2023 | 86 | 29 | 50.88% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Sep 30, 2022 | 75 | 28 | 59.57% |
| Jun 30, 2022 | 72 | 52 | 260.00% |
| Mar 31, 2022 | 57 | 37 | 185.00% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Sep 30, 2021 | 47 | 35 | 291.67% |
| Jun 30, 2021 | 20 | - | - |
| Mar 31, 2021 | 20 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 71 |
| aTyr Pharma | 65 |
| PolyPid | 60 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
| eXoZymes | 31 |
| Oncolytics Biotech | 28 |
| TuHURA Biosciences | 19 |
BMEA News
- 4 weeks ago - Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - GlobeNewsWire
- 2 months ago - Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - GlobeNewsWire
- 2 months ago - Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 2 months ago - Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 2 months ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Biomea Fusion to Participate at Upcoming Investor Conferences - GlobeNewsWire